Endologix's (ELGX) Nellix Seen as Best Growth Story In Medtech, Piper Jaffray Says
Tweet Send to a Friend
Piper Jaffray analyst Brooks West reiterated an Overweight rating and boosted his price target on Endologix (NASDAQ: ELGX) to $21.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
